Literature DB >> 32450297

Impaired Amyloid Beta Clearance and Brain Microvascular Dysfunction are Present in the Tg-SwDI Mouse Model of Alzheimer's Disease.

Hector Rosas-Hernandez1, Elvis Cuevas1, James B Raymick1, Bonnie L Robinson1, Sumit Sarkar2.   

Abstract

Alzheimer's disease (AD) pathology is characterized by amyloid plaques containing amyloid beta (Aβ) peptides, neurofibrillary tangles containing hyperphosphorylated tau protein, and neuronal loss. In addition, Aβ deposition in brain microvessels, known as cerebral amyloid angiopathy (CAA), increases blood-brain barrier (BBB) permeability and induces vascular dysfunction which aggravates AD pathology. The aim of the present study was to characterize neurovascular dysfunction in the Tg-SwDI mouse model of AD. Isolated brain capillaries from wild type (WT) and Tg-SwDI mice were used to evaluate the expression of monomeric and aggregated forms of Aβ, P-glycoprotein (P-gp), the receptor for advance glycation end-products (RAGE) and the tight junction (TJs) proteins occludin and claudin-5. Cultured brain endothelial cells were used to analyze barrier function via fluorescein flux. Isolated capillaries from Tg-SwDI mice contained increased levels of aggregated and oligomeric Aβ compared to WT animals. Isolated capillaries from Tg-SwDI had decreased levels of P-gp, which transports Aβ from brain to blood, and increased levels of RAGE, which transports Aβ from blood to brain. In addition, the TJ protein occludin was decreased in Tg-SwDI mice relative to WT mice, which correlated with an increase in BBB permeability in cultured brain endothelial cells. These findings demonstrated that Tg-SwDI mice exhibit Aβ aggregation that is due, in part, to impaired Aβ clearance driven by both a decrease in P-gp and increase in RAGE protein levels in brain capillaries. Aβ aggregation promotes a decrease in the expression of the TJ protein occludin, and as consequence an increase in BBB permeability. Published by Elsevier Ltd.

Entities:  

Keywords:  Alzheimer’s disease; Aβ transporters; amyloid beta (Aβ); blood–brain barrier; permeability; tight junctions

Mesh:

Substances:

Year:  2020        PMID: 32450297     DOI: 10.1016/j.neuroscience.2020.05.024

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  4 in total

Review 1.  Taxifolin: A Potential Therapeutic Agent for Cerebral Amyloid Angiopathy.

Authors:  Satoshi Saito; Masashi Tanaka; Noriko Satoh-Asahara; Roxana Octavia Carare; Masafumi Ihara
Journal:  Front Pharmacol       Date:  2021-02-12       Impact factor: 5.810

Review 2.  The "Cerebrospinal Fluid Sink Therapeutic Strategy" in Alzheimer's Disease-From Theory to Design of Applied Systems.

Authors:  Thomas Gabriel Schreiner; Manuel Menéndez-González; Bogdan Ovidiu Popescu
Journal:  Biomedicines       Date:  2022-06-25

3.  Transcriptomic Profile of Blood-Brain Barrier Remodeling in Cerebral Amyloid Angiopathy.

Authors:  Muyu Situ; Ali Francisco Citalan-Madrid; Svetlana M Stamatovic; Richard F Keep; Anuska V Andjelkovic
Journal:  Front Cell Neurosci       Date:  2022-06-22       Impact factor: 6.147

Review 4.  Relationship Between Amyloid-β Deposition and Blood-Brain Barrier Dysfunction in Alzheimer's Disease.

Authors:  Dong Wang; Fanglian Chen; Zhaoli Han; Zhenyu Yin; Xintong Ge; Ping Lei
Journal:  Front Cell Neurosci       Date:  2021-07-19       Impact factor: 5.505

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.